Our experience with the management of superficial bladder cancer (Transitional Cell Ca), the role of adjuvant intravesical BCG therapy

Authors

  • Safdar Shah
  • Khuda Dad Tarar
  • Suhaib Umar Bhatti
  • Salomi Suhaib

DOI:

https://doi.org/10.21649/akemu.v12i4.958

Keywords:

Carcinoma, Transitional Cell. Bladder Cancer. Cystectomy. Administration, Intravesical. BCG Vaccine. Combined Modality Therapy. Bladder Disease. Carcinoma. Antineoplastic Agents.

Abstract

We present our experience of 52 patients with bladder cancer. 47 patients (90%) were having superficial bladder disease (Ta, T1) who underwent TURBT followed by intravesical BCG postoperatively, 35 patients (67.3%) completed 6 weeks. Course of intravesical BCG with 10 patients (19.3%) showed recurrence of disease after` six month of follow-up. 4 patients (7.6%) left after 2 weeks of intravesical BCG and 3 patients (5.76%) did not take BCG therapy. These patients hade invasive disease and underwent radical cystectomy and two patients had metastatic bladder cancer disease which were advised systemic palliative treatment. We found intravesical BCG as effective and successful adjuvant therapy for superficial bladder cancer.

Published

2016-04-04

How to Cite

Shah, S., Tarar, K. D., Bhatti, S. U., & Suhaib, S. (2016). Our experience with the management of superficial bladder cancer (Transitional Cell Ca), the role of adjuvant intravesical BCG therapy. Annals of King Edward Medical University, 12(4). https://doi.org/10.21649/akemu.v12i4.958

Issue

Section

Articles